New Methodology to Detect SARS-CoV-2 That Produces Reliable Results More Quickly Could Be a Game-Changer
|
By LabMedica International staff writers Posted on 21 Dec 2021 |

A new methodology to detect SARS-CoV-2 that can produce reliable results more quickly than other methods could be a game-changer in COVI-19 testing.
Researchers at the Binghamton University (Binghamton, NY, USA) have developed a nucleic acid sensor that has the potential to speed sample turn-around time while maintaining the sensitivity and specificity parameters that make molecular testing powerful.
Methods to detect SARS-CoV-2, the virus that causes COVID-19, come in two types. The first detects the virus protein or “antigen,” the basis of the rapid tests found at local stores, with results typically coming back in around 15 minutes. The second type are molecular tests designed to detect virus nucleic acid, which can take anywhere from one to three days to return results. In the very specific and sensitive molecular tests, specimens must be shipped to testing labs, where the samples are then processed and analyzed by technicians with specialized training. As a result, they’re considered by scientists as the gold standard for testing due to their reliability, although their long wait time makes them cumbersome for patients.
The nucleic acid sensor developed by the researchers is called an E-beacon and may lead to faster, more accurate test for coronavirus. Enzymatic beacons are engineered “bioconjugates” with two key components: a light-generating enzyme and a DNA probe. The components are stitched together via a recently-patented method. In the E-beacons prepared for SARS-CoV-2, the DNA probe recognizes a specific sequence in the virus’ spike gene; that recognition event in turn causes the light output from the attached enzyme to increase. The more virus nucleic acid in a sample, the brighter the light signal from the enzyme component of the E-beacon.
E-beacons can provide positive or negative results more rapidly than molecular tests, and without the expensive instrumentation required by polymerase chain reaction (PCR) based testing. The E-beacon experiments haven’t yet been done outside the lab, which is the likely next step. However, its applications could be a game-changer. For instance, users can access a walk-up, automated testing device that somewhat resembles a vending machine to deposit a testing swab into a collection port. The molecular tests would then run autonomously within the machine, sending out the results via cell phone in about two hours. E-beacons represent an attractive alternative to the current testing methods, and not just for SARS-CoV-2. Because of their modular design, they can be reconfigured easily for detecting other viral or bacterial pathogens.
“We focused on cutting down the wait time for molecular testing. We developed a nucleic acid sensor - we call it an E-beacon - that has the potential to speed sample turn-around time while maintaining the sensitivity and specificity parameters that make molecular testing so powerful,” said Brian Callahan, Binghamton University Associate Professor of Chemistry. “As of now, our E-beacons appear to be just as specific and even more sensitive than detection methods used in current SARS-CoV-2 molecular tests.”
Related Links:
Binghamton University
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants
Channels
Clinical Chemistry
view channel
Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively
Lung cancer remains difficult to monitor for early progression and treatment resistance, while pulmonary fibrosis continues to pose major challenges for early diagnosis. Clinicians need repeatable, noninvasive... Read more
Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection
Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read moreMolecular Diagnostics
view channel
Breast Cancer-Specific Signatures Link Genome Instability to Outcomes
Genomic instability is a hallmark of cancer, but most genomic analyses have relied on broad signatures shared across multiple malignancies, limiting their precision for individual tumor types.... Read more
Whole-Genome MRD Test Detects Early Recurrence in Muscle-Invasive Bladder Cancer
Bladder cancer is among the most common malignancies in the United States, with about 85,000 new cases each year. The muscle-invasive form accounts for roughly one quarter of diagnoses and carries a high... Read more
Blood Test Detects Early Nonresponse in Metastatic Prostate Cancer
Prostate cancer is the most common cancer in the U.K., with more than 64,000 men diagnosed and 12,000 deaths each year. For the roughly 10,000 men annually with advanced disease, early assessment of treatment... Read more
FDA-Cleared Genomic Profiling Assay Guides Treatment Selection in Solid Tumors
Datar Cancer Genetics (DCG; Nashik, India), a global precision oncology company, has announced that its tissue-based comprehensive genomic profiling (CGP) assay for all solid tumors, CellDx-Tissue, has received U.... Read moreHematology
view channel
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read moreImmunology
view channel
Routine TB Screening Test May Reveal Immune Aging and Mortality Risk
Immune aging is associated with weaker responses to vaccination, greater risks of infection, and higher levels of inflammation. Leveraging routinely ordered laboratory tests to quantify that responsiveness... Read more
Biomarkers and Molecular Testing Advance Precision Allergy Care
Allergic diseases often present with similar symptoms but can be driven by distinct biological mechanisms, making standardized care inefficient for many patients. Historically, individuals with pollen... Read moreMicrobiology
view channel
Study Finds Hidden Mpox Infections May Drive Ongoing Spread
Mpox continues to circulate despite vaccination, and many cases show no known link to a symptomatic partner. The role of people without symptoms has remained uncertain, limiting clarity on how transmission persists.... Read more
Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
Tuberculosis is the leading cause of death among people living with HIV, and diagnosis in hospital settings remains difficult. Symptoms are often non-specific, disease can be extrapulmonary, and many patients... Read morePathology
view channel
Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images
Gene expression profiling can inform tumor biology and treatment selection, but spatial assays remain costly and time-consuming. Results can take weeks and cost thousands of dollars, limiting large-scale... Read more
AI Pathology Test Receives FDA Breakthrough for Bladder Cancer Risk Stratification
Non–muscle invasive bladder cancer has highly variable outcomes, complicating surveillance and treatment planning. Risk assessment typically relies on stage, grade, and tumor size, leaving uncertainty... Read moreTechnology
view channel
Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
Limited access to general practitioners and pathology services can delay diagnosis and monitoring for people in regional and remote communities. Rapid, on-the-spot testing can shorten turnaround times... Read more
Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
Latent tuberculosis remains a substantial testing workload for clinical laboratories as screening programs expand. Despite this growth, only about 40% of testing has shifted from traditional skin tests... Read moreIndustry
view channel
AI-Powered Multi-Functional Analyzer Wins German Innovation Award
Hematology services are increasingly delivered across distributed care settings, where limited staffing and complex workflows can extend turnaround times. Advanced morphology review still often depends... Read more









